VERASTEM INC. news, videos and press releases
For more news please use our advanced search feature.
VERASTEM INC. - More news...
VERASTEM INC. - More news...
- Verastem Oncology Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates
- Verastem Oncology Announces Multiple Data Presentations at Society of Gynecologic Oncology 2025 Annual Meeting on Women’s Cancer
- Verastem Oncology to Present at the Guggenheim SMID Cap Biotech Conference
- Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
- Verastem Oncology Names Matthew E. Ros as Chief Operating Officer
- Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
- Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Announces FDA Acceptance and Priority Review of New Drug Application for Avutometinib in Combination with Defactinib for the Treatment of Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer
- Verastem Oncology Provides a Clinical Update for RAMP 203 Trial in Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
- Verastem Oncology to Present at the 7th Annual Evercore ISI HealthCONx Conference
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verastem, Inc. - VSTM
- Verastem Oncology Reports Second Quarter 2023 Financial Results and Highlights Recent Company Progress
- Verastem Oncology Announces Promotion of Dan Paterson to Chief Executive Officer
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Verastem Oncology Announces Design for Confirmatory Trial of Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer
- Verastem Oncology Announces Pricing of $85.0 Million Public Offering of Common Stock and Pre-Funded Warrants
- Verastem Oncology Announces Reverse Stock Split
- Updated Data from Part A of Verastem Oncology's RAMP 201 Trial Show an Objective Response Rate of 45% in Patients with Recurrent Low-Grade Serous Ovarian Cancer Treated with Avutometinib and Defactinib
- Verastem Oncology Appoints Karin Tollefson, PhD, to Board of Directors
- Verastem Oncology Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress
- Verastem Oncology to Participate in Upcoming Investor Conferences
- New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial Evaluating Avutometinib and Defactinib in Recurrent Low-Grade Serous Ovarian Cancer to be Presented at the American Society of Clinical Oncology Annual Meeting
- Verastem Oncology to Present at the Stifel 2023 Virtual Targeted Oncology Days
- Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- New Verastem Oncology Initiative, Let’s Talk About LGSOC, Calls Attention to Rare Form of Ovarian Cancer
